Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

79%

11 trials in Phase 3/4

Results Transparency

10%

1 of 10 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

10(71.4%)

Phase 2

2(14.3%)

N/A

1(7.1%)

Phase 3

1(7.1%)

14Total

Phase 4(10)

Phase 2(2)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT07357584Phase 4Not Yet Recruiting

Efficacy and Safety of Doravirine in the Rapid Initiation

Role: lead

NCT07099287Not ApplicableCompleted

Advancing Smoking Cessation Among Transgender

Role: collaborator

NCT04880395Phase 4Completed

Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3

Role: lead

NCT05005156Phase 2Completed

Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV

Role: lead

NCT05293223Phase 2Completed

Phase IIB Study of Recombinant Novel Coronavirus Vaccine

Role: lead

NCT06588257Phase 4Active Not Recruiting

Acceptability of the HPV Vaccine and Anal HPV in Transgender Women and Men Who Have Sex With Men: A Pilot Study

Role: lead

NCT04560881Phase 3Completed

Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)

Role: collaborator

NCT04788407Phase 4Unknown

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts

Role: lead

NCT03033836Phase 4Completed

Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women

Role: lead

NCT02770508Phase 4Completed

Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects

Role: lead

NCT02211482Phase 4Completed

Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study

Role: lead

NCT00159224Phase 4Completed

Induction-maintenance of Lopinavir/r in HIV-infected Subjects

Role: lead

NCT01379326Phase 4Completed

Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2

Role: collaborator

NCT01013987Phase 4Unknown

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

Role: lead

All 14 trials loaded